VNRX — VOLITIONRX LTD

NYSE · Health Care · Life Sciences Tools & Services · CIK 93314 ·
Last close
$0.39
Market Cap
$5.34M
52W High
$3.20
52W Low
$0.37
ADV30
810,773
Next earnings
2026-11-12
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 985,076 -5,228,321 -6,664,774 9,036,483 3,102,817 42,396,412
Dec 2025 447,034 -4,731,280 -6,270,832 6,901,227 1,117,028 42,494,038
Sep 2025 627,277 -4,868,806 -5,378,358 6,448,885 199,407 42,398,447
Jun 2025 406,688 -6,221,816 -6,284,078 8,704,790 2,255,996 41,803,112

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,665,448
Investing CF
$-96,964
Financing CF
$21,041,954
CapEx
$-98,772
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-4.29
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-259,566,144
Inventory
Receivables
$252,242
ST Investments
EBIT TTM
$-21,761,613
Pretax Income TTM
$-24,730,259
Interest Exp TTM
$2,968,646
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,458,044
EBITDA
$-18,572,584
Free Cash Flow
$-9,213,488
Enterprise Value
$12,935,317
Total Cash
$2,790,994
Total Debt
$11,410,300
Shares Out
13,649,384
Trailing EPS
$-3.85
Book Value
$-4.03
ROE
ROA
-142.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,727,384 -21,222,056 -23,357,027 6,901,227 42,494,038 -19,683,334
Dec 2024 1,233,511 -26,921,602 -26,967,836 9,399,523 35,507,259 -25,893,624
Dec 2023 775,302 -35,773,244 -35,319,078 27,950,498 36,662,720 -18,062,999
Dec 2022 306,392 -30,550,647 -30,268,793 18,295,054 21,422,016 -15,277,742

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.85

Peers — same industry

TickerNameMarket CapLastDaily %
BMRA BIOMERICA INC $5.19M $1.68
CDIO Cardio Diagnostics Holdings, Inc. $5.70M $1.92
ISPC iSpecimen Inc. $3.95M $1.57
BUDZ WEED, INC. $3.71M $0.03
TRIB TRINITY BIOTECH PLC $8.40M $10.33

News headlines (Yahoo Finance, 1h cache)

Volition (VNRX) Q2 2026 Earnings Call Transcript
2026-08-20 23:28 · Yahoo
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
2026-08-05 12:17 · Yahoo
Volition Advances Nu.Q® NETs Platform Towards Commercialization
2026-07-30 12:17 · Yahoo
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
2026-07-07 12:17 · Yahoo
VolitionRx Announces Pricing of $4.6 Million Public Offering
2026-06-07 22:30 · Yahoo
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
2026-06-03 12:12 · Yahoo
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
2026-05-27 12:17 · Yahoo
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts
2026-05-24 11:49 · Yahoo
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
2026-05-15 23:02 · Yahoo
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
2026-05-14 20:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.